Donald L. Hagan LLC Grows Stock Holdings in Scilex Holding (NASDAQ:SCLX)

Donald L. Hagan LLC raised its position in shares of Scilex Holding (NASDAQ:SCLX) by 49.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 52,343 shares of the company’s stock after buying an additional 17,245 shares during the quarter. Donald L. Hagan LLC’s holdings in Scilex were worth $107,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of SCLX. State Street Corp purchased a new position in shares of Scilex during the 1st quarter valued at approximately $60,070,000. BlackRock Inc. lifted its holdings in Scilex by 146,859.5% in the 2nd quarter. BlackRock Inc. now owns 5,458,076 shares of the company’s stock valued at $30,401,000 after purchasing an additional 5,454,362 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Scilex by 200.6% in the 3rd quarter. Vanguard Group Inc. now owns 8,076,392 shares of the company’s stock valued at $11,307,000 after purchasing an additional 5,389,338 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in Scilex in the 3rd quarter valued at $665,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Scilex during the 1st quarter worth $3,574,000. 69.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Scilex in a report on Monday, December 4th.

Scilex Stock Performance

Shares of NASDAQ SCLX traded down $0.02 during trading on Friday, hitting $1.59. 654,736 shares of the company were exchanged, compared to its average volume of 1,435,646. Scilex Holding has a 12-month low of $0.90 and a 12-month high of $16.90. The company has a fifty day moving average price of $1.61 and a 200-day moving average price of $1.61. The firm has a market capitalization of $264.24 million, a PE ratio of -1.23 and a beta of 0.76.

Scilex Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.